CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Nilotinib

尼洛替尼 杂质对照品Nilotinib Impurities

EP40 个杂质条目40 impurity entries

本页汇总 尼洛替尼 的 40 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 40 impurity reference standards of Nilotinib with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 尼洛替尼(Nilotinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA validated stability-indicative UPLC method for nilotinib hydrochloride for the determination of process-related and degradation impurities
    Journal of chromatographic science · 2014 · Kondra SB et al.  ·  PMID 24029617  ·  DOI
  2. 杂质研究Impurity studiesA systematic approach for stability-indicating HPLC method optimization for Nilotinib bulk through design of experiments: Application towards characterization of base degradation products by mass spectrometry
    Annales pharmaceutiques francaises · 2021 · Narenderan ST et al.  ·  PMID 33242483  ·  DOI
  3. 杂质研究Impurity studiesA Quality by Design (QbD) driven gradient high performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2024 · Sen S, Ranjan OP  ·  PMID 38991258  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisThe synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib
    Organic & biomolecular chemistry · 2013 · Deadman BJ et al.  ·  PMID 23247657  ·  DOI
  • 合成方法SynthesisCompletely N1-selective palladium-catalyzed arylation of unsymmetric imidazoles: application to the synthesis of nilotinib
    Journal of the American Chemical Society · 2012 · Ueda S et al.  ·  PMID 22126442  ·  DOI

尼洛替尼 —— 原料药与杂质对照品Nilotinib — drug substance & impurities

共 41 个条目(含原料药本体)41 items incl. the drug substance
Nilotinib structure
EP原料药 APIAPI
尼洛替尼Nilotinib
Nilotinib
CAS No.641571-10-0
Chemical FormulaC28H22F3N7O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 15 (Nilotinib EP Impurity A) structure
EPA
尼洛替尼杂质15 (尼洛替尼EP杂质A)Nilotinib Impurity 15 (Nilotinib EP Impurity A)
Nilotinib Impurity 15 (Nilotinib EP Impurity A)
CAS No.641571-11-1
Chemical FormulaC11H10F3N3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 17 (Nilotinib Hydrochloride Monohydrate EP Impurity B) structure
EPB
尼洛替尼杂质17 (盐酸尼洛替尼一水合物EP杂质B)Nilotinib Impurity 17 (Nilotinib Hydrochloride Monohydrate EP Impurity B)
Nilotinib Impurity 17 (Nilotinib Hydrochloride Monohydrate EP Impurity B)
CAS No.18595-18-1
Chemical FormulaC9H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 18 (Nilotinib EP Impurity C) structure
EPC
尼洛替尼杂质18 (尼洛替尼EP杂质C)Nilotinib Impurity 18 (Nilotinib EP Impurity C)
Nilotinib Impurity 18 (Nilotinib EP Impurity C)
CAS No.2458-12-0
Chemical FormulaC8H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 6 (Nilotinib EP Impurity D) structure
EPD
尼洛替尼杂质6 (尼洛替尼EP杂质D)Nilotinib Impurity 6 (Nilotinib EP Impurity D)
Nilotinib Impurity 6 (Nilotinib EP Impurity D)
CAS No.641569-94-0
Chemical FormulaC17H14N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 10 (Nilotinib EP Impurity E) structure
EPE
尼洛替尼杂质10 (尼洛替尼EP杂质E)Nilotinib Impurity 10 (Nilotinib EP Impurity E)
Nilotinib Impurity 10 (Nilotinib EP Impurity E)
CAS No.2119583-26-3
Chemical FormulaC27H20F3N7O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 11 (Nilotinib EP Impurity F) structure
EPF
尼洛替尼杂质11 (尼洛替尼EP杂质F)Nilotinib Impurity 11 (Nilotinib EP Impurity F)
Nilotinib Impurity 11 (Nilotinib EP Impurity F)
CAS No.2119583-24-1
Chemical FormulaC29H24F3N7O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 12 (Nilotinib EP Impurity G) structure
EPG
尼洛替尼杂质12 (尼洛替尼EP杂质G)Nilotinib Impurity 12 (Nilotinib EP Impurity G)
Nilotinib Impurity 12 (Nilotinib EP Impurity G)
CAS No.917392-54-2
Chemical FormulaC18H16N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 13 (Nilotinib EP Impurity H) structure
EPH
尼洛替尼杂质13 (尼洛替尼EP杂质H)Nilotinib Impurity 13 (Nilotinib EP Impurity H)
Nilotinib Impurity 13 (Nilotinib EP Impurity H)
CAS No.641571-15-5
Chemical FormulaC28H22F3N7O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 1 structure
1
尼洛替尼杂质1Nilotinib Impurity 1
Nilotinib Impurity 1
CAS No.641571-16-6
Chemical FormulaC11H10F3N3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 2 structure
2
尼洛替尼杂质2Nilotinib Impurity 2
Nilotinib Impurity 2
CAS No.2119583-28-5
Chemical FormulaC12H12F3N3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 3 structure
3
尼洛替尼杂质3Nilotinib Impurity 3
Nilotinib Impurity 3
CAS No.641571-06-4
Chemical FormulaC11H10F3N3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 4 structure
4
尼洛替尼杂质4Nilotinib Impurity 4
Nilotinib Impurity 4
CAS No.2119583-27-4
Chemical FormulaC12H12F3N3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 5 structure
5
尼洛替尼杂质5Nilotinib Impurity 5
Nilotinib Impurity 5
CAS No.66521-66-2
Chemical FormulaC9H8N4
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 7 structure
7
尼洛替尼杂质7Nilotinib Impurity 7
Nilotinib Impurity 7
CAS No.926922-18-1
Chemical FormulaC19H15F3IN3O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 8 structure
8
尼洛替尼杂质8Nilotinib Impurity 8
Nilotinib Impurity 8
CAS No.1246817-85-5
Chemical FormulaC28H22F3N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 9 structure
9
尼洛替尼杂质9Nilotinib Impurity 9
Nilotinib Impurity 9
CAS No.66521-65-1
Chemical FormulaC9H8N4
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 16 structure
16
尼洛替尼杂质16Nilotinib Impurity 16
Nilotinib Impurity 16
CAS No.641571-05-3
Chemical FormulaC28H22F3N7O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 19 structure
19
尼洛替尼杂质19Nilotinib Impurity 19
Nilotinib Impurity 19
CAS No.641571-13-3
Chemical FormulaC12H9F3N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 20 structure
20
尼洛替尼杂质20Nilotinib Impurity 20
Nilotinib Impurity 20
CAS No.641570-89-0
Chemical FormulaC11H10F3N3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 22 structure
22
尼洛替尼杂质22Nilotinib Impurity 22
Nilotinib Impurity 22
CAS No.2486-70-6
Chemical FormulaC8H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 23 structure
23
尼洛替尼杂质23Nilotinib Impurity 23
Nilotinib Impurity 23
CAS No.859026-97-4
Chemical FormulaC9H11N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 24 structure
24
尼洛替尼杂质24Nilotinib Impurity 24
Nilotinib Impurity 24
CAS No.64818-80-0
Chemical FormulaC10H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 25 structure
25
尼洛替尼杂质25Nilotinib Impurity 25
Nilotinib Impurity 25
CAS No.917391-28-7
Chemical FormulaC12H10F3N3O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 29 structure
29
尼洛替尼杂质29Nilotinib Impurity 29
Nilotinib Impurity 29
CAS No.122228-09-5
Chemical FormulaC9H11N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 30 (N-Nitroso Nilotinib) structure
30
尼洛替尼杂质30 (N-亚硝基尼洛替尼)Nilotinib Impurity 30 (N-Nitroso Nilotinib)
Nilotinib Impurity 30 (N-Nitroso Nilotinib)
CAS No.2925306-68-7
Chemical FormulaC28H21F3N8O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 35 structure
35
尼洛替尼杂质35Nilotinib Impurity 35
Nilotinib Impurity 35
CAS No.2139382-75-3
Chemical FormulaC28H22F3N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 40 structure
40
尼洛替尼杂质40Nilotinib Impurity 40
Nilotinib Impurity 40
CAS No.1807608-52-1
Chemical FormulaC28H22F3N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 44 structure
44
尼洛替尼杂质44Nilotinib Impurity 44
Nilotinib Impurity 44
CAS No.641569-96-2
Chemical FormulaC11H15N3O2·HNO3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 45 structure
45
尼洛替尼杂质45Nilotinib Impurity 45
Nilotinib Impurity 45
CAS No.1807606-80-9
Chemical FormulaC28H22F3N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 46 structure
46
尼洛替尼杂质46Nilotinib Impurity 46
Nilotinib Impurity 46
CAS No.1807607-72-2
Chemical FormulaC28H20F3N7O3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 48 structure
48
尼洛替尼杂质48Nilotinib Impurity 48
Nilotinib Impurity 48
CAS No.915711-42-1
Chemical FormulaC19H17F3N4O
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 49 structure
49
尼洛替尼杂质49Nilotinib Impurity 49
Nilotinib Impurity 49
CAS No.1157857-29-8
Chemical FormulaC19H15F3N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 50 structure
50
尼洛替尼杂质50Nilotinib Impurity 50
Nilotinib Impurity 50
CAS No.1883666-44-1
Chemical FormulaC33H31F3N8O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 51 structure
51
尼洛替尼杂质51Nilotinib Impurity 51
Nilotinib Impurity 51
CAS No.866998-34-7
Chemical FormulaC9H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 52 structure
52
尼洛替尼杂质52Nilotinib Impurity 52
Nilotinib Impurity 52
CAS No.1157209-79-4
Chemical FormulaC16H16N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 53 structure
53
尼洛替尼杂质53Nilotinib Impurity 53
Nilotinib Impurity 53
CAS No.1132811-44-9
Chemical FormulaC16H16N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 54 structure
54
尼洛替尼杂质54Nilotinib Impurity 54
Nilotinib Impurity 54
CAS No.142031-67-2
Chemical FormulaC9H8Br2O2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 55 structure
55
尼洛替尼杂质55Nilotinib Impurity 55
Nilotinib Impurity 55
CAS No.2089291-49-4
Chemical FormulaC10H10BrClO2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 56 structure
56
尼洛替尼杂质56Nilotinib Impurity 56
Nilotinib Impurity 56
CAS No.335013-00-8
Chemical FormulaC10H10BrClO2
Purity>95%询价On request
10mg25mg50mg100mg
Nilotinib Impurity 57 structure
57
尼洛替尼杂质57Nilotinib Impurity 57
Nilotinib Impurity 57
CAS No.1186620-41-6
Chemical FormulaC17H13ClN4O2
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

尼洛替尼 —— 研究文献与合成路线Nilotinib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 尼洛替尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Nilotinib. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A validated stability-indicative UPLC method for nilotinib hydrochloride for the determination of process-related and degradation impurities
    Kondra SB, Madireddy V, Chilukuri M, et al. · Journal of chromatographic science · 2014 · 被引 3cited 3
  2. A systematic approach for stability-indicating HPLC method optimization for Nilotinib bulk through design of experiments: Application towards characterization of base degradation products by mass spectrometry
    Narenderan ST, Babu B, Srikanth J, et al. · Annales pharmaceutiques francaises · 2021 · 被引 2cited 2
  3. Imatinib and Nilotinib inhibit Bcr-Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox
    Landry WD, Woolley JF, Cotter TG · Leukemia research · 2013 · 被引 23cited 23
  4. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models
    Hebron ML, Lonskaya I, Moussa CE · Human molecular genetics · 2013 · 被引 271cited 271
  5. Correction to: Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models
    — · Human molecular genetics · 2023 · 被引 2cited 2

合成与制备工艺专利Synthesis & process patents

  1. PREPARATION OF NILOTINIB AND INTERMEDIATES THEREOF
    YEORI ADI, WANG YANLING, LI JIE, ZHU JIRANG, et al. · 公开号 WO2010060074WO2010060074 · 2010
  2. NILOTINIB INTERMEDIATES AND PREPARATION THEREOF
    WANG YANLING, LI JIE, KANSAL VINOD KUMAR, ZHU JIRANG, et al. · 公开号 WO2010009402WO2010009402 · 2010
  3. NILOTINIB INTERMEDIATES AND PREPARATION THEREOF
    WANG YANLING, LI JIE, KANSAL VINOD KUMAR, ZHU JIRANG, et al. · 公开号 US2010016590US2010016590 · 2010
  4. Nilotinib intermediates and preparation thereof
    WANG YANLING, LI JIE, KANSAL VINOD KUMAR, ZHU JIRANG, et al. · 公开号 EP2305667EP2305667 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

尼洛替尼 杂质谱研究要点Nilotinib — impurity profiling notes

下面这些是拿到 尼洛替尼 的 41 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 41 impurity entries for Nilotinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances